《新股消息》周杰倫概念股巨星傳奇集團通過聯交所上市聆訊
據聯交所文件顯示,巨星傳奇集團有限公司周三(24日)通過上市聆訊。
據資料顯示,公司業務營運包括兩個分部,即新零售分部及IP創造及營運分部,各分部均可成為其自身的收入來源,而公司的IP創造及營運分部亦可產生協同效應,作為營銷工具之一來推廣新零售產品。
該新零售業務及IP創造及營運業務均倚賴周杰倫。於往績記錄(2019至2022年)期間,新零售分部下涉及周杰倫或其相關IP的宣傳活動的產品分別佔公司總收入的83%、72.8%、64.8%及45.2%,而公司圍繞周杰倫或由其作為表演者之一的IP創造及營運佔總收入的5.7%、19.6%、9.1%及13.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.